References
- Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic mono therapy and polypharmacy in the naturalistic treatment of schizo phrenia with atypical antipsychotic. BMC Psychiatry 2005;5:26
- Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 2004;65:1377–88
- Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313–27
- Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425–6
- Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002;28:105–9
- Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in anti psychotic combination therapy of schizophrenia and schizo-affective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75–84
- Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv 2006;57:127–9
- Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9–15
- Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002;159:1932–5
- Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700–6
- Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine, and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254–65
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76
- Guy W, editor. ECDEU assessment manual for psycho-pharmacology. Washington (DC): US Department of Health, Education, and Welfare; 1976. p. 218–22 [Publication ADM 76–338]
- IMS Health, National Disease and Therapeutic Index (NDTI), Schizophrenia Population, MAT December 2002 and December 2003
- Rupnow M, Markowitz J. Psychotropic polypharmacy in Medicaid subjects with schizophrenia [poster]. APA’s Institute on Psychiatric Services; October 29–November 2, 2003; Boston, MA